Arcadia Pharmaceuticals (ACAD, Financial) experienced a notable stock price increase of 5.03%, reaching $18.15 per share. The trading volume was 1.09 million shares with a turnover rate of 0.66% and a volatility of 4.25%. Recent financial reports show revenue of $250 million, a net profit of $32.77 million, and earnings per share of $0.20. The company has a price-to-earnings ratio of 23.26.
Among 20 analysts, 65% recommend buying, 30% suggest holding, and 5% advise selling. The biotechnology sector saw an overall increase of 0.82%. Arcadia focuses on developing biopharmaceutical products for central nervous system disorders, including Parkinson's, Alzheimer's, and schizophrenia, and seeks to acquire complementary products and drug candidates.
